Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCI 007 是一种具有细胞毒性的选择性白血病抑制剂,在MLL 重排的敏感系婴幼儿白血病细胞中,IC50为2.5-6.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 536 | 现货 | ||
2 mg | ¥ 798 | 现货 | ||
5 mg | ¥ 1,360 | 现货 | ||
10 mg | ¥ 2,180 | 现货 | ||
25 mg | ¥ 3,690 | 现货 | ||
50 mg | ¥ 5,290 | 现货 | ||
100 mg | ¥ 7,490 | 现货 | ||
500 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,430 | 现货 |
产品描述 | CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485 |
体外活性 | small molecule CCI-007 was identified as a compound that selectively and significantly decreased the viability of a subset of MLL-r and related leukemia cell lines with CALM-AF10 and SET-NUP214 translocation.?CCI-007 induced a rapid caspase-dependent apoptosis with mitochondrial depolarization within twenty-four hours of treatment.?CCI-007 altered the characteristic MLL-r gene expression signature in sensitive cells with downregulation of the expression of HOXA9, MEIS1, CMYC and BCL2, important drivers in MLL-r leukemia, within a few hours of treatment.?MLL-r leukemia cells that were resistant to the compound were characterised by significantly higher baseline gene expression levels of MEIS1 and BCL2 in comparison to CCI-007 sensitive MLL-r leukemia cells. |
分子量 | 336.36 |
分子式 | C15H16N2O5S |
CAS No. | 939228-52-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (74.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.973 mL | 14.865 mL | 29.7301 mL | 74.3251 mL |
5 mM | 0.5946 mL | 2.973 mL | 5.946 mL | 14.865 mL | |
10 mM | 0.2973 mL | 1.4865 mL | 2.973 mL | 7.4325 mL | |
20 mM | 0.1487 mL | 0.7433 mL | 1.4865 mL | 3.7163 mL | |
50 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4865 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CCI-007 939228-52-1 Apoptosis Chromatin/Epigenetic Histone Methyltransferase MLL-r CCI 007 CALM-AF10 HOXA9 MEIS1 CCI007 CMYC SET-NUP214 inhibit Inhibitor inhibitor